Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 801–900 of 1,002
GENETICALLY MODIFIED MICE IN NEUROPHARMACOLOGY
Brusa, R. (1999) · Pharmacological Research · doi:10.1006/phrs.1998.0457 · Cited by 29
Facchinetti, F., Fasolato, C., DELGIUDICE, E., Burgo, A., Furegato, S., Fusco, M., Basso, E., Seraglia, R., D'Arrigo, A. M., & Leon, A.-S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.006 · Cited by 22
Eskandari-Sedighi, G., Daude, N., Gapeshina, H., Sanders, D. W., Kamali-Jamil, R., Yang, J., Shi, B., Wille, H., Ghetti, B., Diamond, M. I., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0215-7 · Cited by 22
“Tet vector [51] is consistent with position-independent, pan-neuronal expression of transgene-encoded mRNA observed in other uses of this vector [29, 52, 53]; in this case it produces a comparatively uniform level of Tau substrate considered in a neuroanatomical sense (Figs.”
Self-citationThe Spectrum of Genetic Risk in Alzheimer Disease
Karagas, N. E., Young, J. E., Blue, E., & Jayadev, S. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200224 · Cited by 25
Cell competition from development to neurodegeneration
RODRIGUES, M. C., Couceiro, J., & Moreno, E. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048926 · Cited by 24
Wuli, W., Lin, S., Chen, S., Tannous, B. A., Huang, W.-S., Woon, P. Y., Wu, Y., Yang, H., Chen, Y.-C., Fleming, R. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810554 · Cited by 23
β‐Amyloid 1‐42 induces physiological transcriptional regulation of BACE1
Piccini, A., Borghi, R., Guglielmotto, M., Tamagno, E., Cirmena, G., Garuti, A., Pollero, V., Cammarata, S., Fornaro, M., Messa, M., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07834.x · Cited by 22
“the major cause of early-onset familial AD, induce an altered c-secretase cleavage, leading to a relative increased production of Ab 42 species (Citron et al. 1997).”
BackgroundNovel presenilin mutations within Moroccan patients with Early-Onset Alzheimer’s Disease
Kadmiri, N. E., Zaïd, N., Zaid, Y., Tadevosyan, A., Hachem, A., Dubé, M., Hamzi, K., Moutawakil, B. E., Slassi, I., & Nadifi, S. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.03.052 · Cited by 24
Expanded high-resolution genetic study of 109 Swedish families with Alzheimer's disease
Sillén, A., Andrade, J., Lilius, L., Forsell, C., Axelman, K., Odeberg, J., Winblad, B. G., & Graff, C. (2007) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201946 · Cited by 23
Tucker, S. M. F., Borchelt, D., & Troncoso, J. C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815f38d2 · Cited by 28
“Mutations found in familial AD lead to altered APP processing, with increased generation of AA42 and consequent deposition of this peptide into aggregates (3) (reviewed in [4]).”
BackgroundAnimal models of cognitive dysfunction
Tayebati, S. K. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.026 · Cited by 29
N‐cadherin‐based adhesion enhances Aβ release and decreases Aβ42/40 ratio
Uemura, K., Lill, C. M., Banks, M., Asada, M., Aoyagi, N., Andō, K., Kubota, M., Kihara, T., Nishimoto, T., Sugimoto, H., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05760.x · Cited by 25
“Most of the PS1 mutations associated with familial AD (FAD) are known to increase the ratio of Ab42–Ab40 (Ab42/40 ratio), thereby increasing the more aggregation-prone Ab42 relative to Ab40 (Citron et al. 1997), which is considered at present to be an important molecular background of FAD pathogenesis.”
InfluentialNeuroprotective effects of estradiol-17β: implications for psychiatric disorders
Kölsch, H., & Rao, M. L. (2002) · Archives of Women s Mental Health · doi:10.1007/s00737-002-0005-1 · Cited by 22
Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer’s Disease
Wolfe, M. S. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00830 · Cited by 21
Yang, J. J. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-01907-2 · Cited by 21
“Studies in human familial AD have revealed that mutations in the presenilin proteins (PSEN1; PSEN2) and amyloid precursor protein (APP) contribute to the accumulation of amyloidbeta (Aβ) protein [5, 6], which is a hallmark of AD progression that leads to eventual cognitive impairment.”
BackgroundAmyloid-beta peptide Aβp3-42 affects early aggregation of full-length Aβ1-42
Sanders, H. M., Lust, R. M., & Teller, J. K. (2009) · Peptides · doi:10.1016/j.peptides.2009.01.027 · Cited by 25
“mutations in genes encoding either APP or presenilins 1 or 2, which participate in APP proteolytic processing among other genes [1,3–6,8,13,14,26,33].”
BackgroundBorchelt, D., Lee, M. K., Gonzales, V., Slunt, H. H., Ratovitski, T., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00280-9 · Cited by 21
Self-citationDay, G. S., Musiek, E. S., Roe, C. M., Norton, J. B., Goate, A., Cruchaga, C., Cairns, N. J., & Morris, J. C. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1236 · Cited by 23
DNA damage-inducing agents elicit γ-secretase activation mediated by oxidative stress
Jin, S. M., Cho, H., Jung, E. S., Shim, M.-Y., & Mook‐Jung, I. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.49 · Cited by 22
Novel aspects of accumulation dynamics and Aβ composition in transgenic models of AD
Lewis, H. D., Beher, D., Smith, D., Hewson, L., Cookson, N., Reynolds, D. S., Dawson, G. R., Jiang, M., der Ploeg, L. H. T. V., Qian, S., et al. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.009 · Cited by 22
“5), as previously observed in conditioned media, plasma [31] and other transgenic lines [3,8,11,15].”
BackgroundSudoh, S., Hua, G., Kawamura, Y., Maruyama, K., Komano, H., & Yanagisawa, K. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01206.x · Cited by 22
Melcangi, R. C., Magnaghi, V., Cavarretta, I., Zucchi, I., Bovolin, P., D'Urso, D., & Martini, L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990515)56:4<349::aid-jnr3>3.0.co;2-h · Cited by 123
Structural and Chemical Biology of Presenilin Complexes
Johnson, D. S., Li, Y., Pettersson, M., & George‐Hyslop, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024067 · Cited by 21
“Missense mutations in the presenilins alter the relative abundance of amyloid-b (Ab) peptide species produced during presenilin-complexmediated cleavage of APP-C100 following BACE cleavage of APP (Scheuner et al. 1996; Citron et al. 1997; Chávez-Gutiérrez et al. 2012).”
BackgroundTransgenic Models of Alzheimer's Disease
Sugarman, M. C., Hinton, S. F., & LaFerla, F. M. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_2 · Cited by 20
“Alzheimer’s disease-like pathology was accelerated in the double transgenic mice that carried either the A246E or M146L mutation in the PS1 gene and the APPSW gene (32,33,92).”
BackgroundEhling, R., Nosková, L., Stránecký, V., Hartmannová, H., Přistoupilová, A., Hodaňová, K., Benke, T., Kovács, G. G., Ströbel, T., Niedermüller, U., et al. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.01.017 · Cited by 22
“A number of PSEN1missensemutations alter the specificity of γ-secretase cleavage leading to increased proportions of longer forms of amyloid-β peptide (Aβ), which are prone to oligomerization and aggregation in amyloid plaques [9,10].”
Pinto, L. D., Puppin, P. A. L., Behring, V. M., Flinker, D. H., Mercê, A. L. R., Mangrich, A. S., Rey, N. A., & Felcman, J. (2010) · Inorganica Chimica Acta · doi:10.1016/j.ica.2010.04.036 · Cited by 23
Fitzjohn, S. M., Kuenzi, F. M., Morton, R. A., Rosahl, T. W., Lewis, H. D., Smith, D., Seabrook, G. R., & Collingridge, G. L. (2010) · Molecular Brain · doi:10.1186/1756-6606-3-21 · Cited by 24
“PS1 is intimately associated with the cleavage of APP at the γ-secretase site and familial AD mutations in PS1, such as the A246E mutation occurring in transmembrane domain 6 of the presenilin protein [5,6], alter the efficiency of cleavage of APP and accelerate the production of Aβ [3,6-8].”
Herzig, M. C., Paganetti, P., Staufenbiel, M., & Jucker, M. (2007) · Neurodegenerative Diseases · doi:10.1159/000101837 · Cited by 21
Eyre, L. J., Rabbitt, E. H., Bland, R., Hughes, S. V., Cooper, M. S., Sheppard, M. C., Stewart, P. M., & Hewison, M. (2001) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010601)81:3<453::aid-jcb1059>3.0.co;2-z · Cited by 35
Self-citationHüll, M., Fiebich, B. L., Dykierek, P., Schmidtke, K., Nitzsche, E. U., Orszagh, M., Deuschl, G., Moser, E. A., Schumacher, M. C., Lücking, C. H., et al. (1998) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050028 · Cited by 22
Transgenic Mouse Models and Human Neurodegenerative Disorders
Deng, H., & Siddique, T. (2000) · Archives of Neurology · doi:10.1001/archneur.57.12.1695 · Cited by 21
Disordered proteins in dementia
Ingelsson, M., & Hyman, B. T. (2002) · Annals of Medicine · doi:10.1080/078538902320322529 · Cited by 20
“Presenilin mutations strongly in ̄uence ®-secretase cleavage and cause increased Ab42 levels in plasma and ®broblasts from patients (23) as well as in transfected cells and transgenic mice brain (24).”
BackgroundAlzheimer’s disease basics: we all should know
Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 20
Lessons from genome‐wide association studies findings in Alzheimer's disease
Moraes, C. F., Lins, T. C. D. L., CARMARGOS, E. F., Naves, J. O. S., Pereira, R. W., & Nóbrega, O. D. T. (2011) · Psychogeriatrics · doi:10.1111/j.1479-8301.2011.00378.x · Cited by 22
Alzheimer's disease: Genetic evidence points to a single pathogenesis
Hardy, J. (2003) · Annals of Neurology · doi:10.1002/ana.10624 · Cited by 20
Immunoglobulin G-Based Steric Hindrance Assay for Protein Detection
Dai, Y., Xu, W., & Liu, C.-C. (2019) · ACS Sensors · doi:10.1021/acssensors.9b01902 · Cited by 21
Kapadia, A., Sharma, K. K., Maurya, I. K., Singh, V., Khullar, M., & Jain, R. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113126 · Cited by 21
PET Imaging in Preclinical Anti-Aβ Drug Development
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U. H., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03277-z · Cited by 20
“Especially the morphology of the plaques appear to differ, where dominant Aβ42 pathology leads to smaller cores and potentially to more diffuse pathology that is less well detected by amyloid radioligands and is likely to require higher molar activity as discussed previously.”
BackgroundInfluentialJuhász, G., Márki, Á., Vass, G., Fülöp, L., Budai, D., Penke, B., Falkay, G., & Szegedi, V. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0947 · Cited by 19
Portelius, E., Fortea, J., Molinuevo, J. L., Gustavsson, M. K., Andréasson, U., & Sánchez‐Valle, R. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.774 · Cited by 21
“These mutations appear to accelerate Aβ plaque formation and have been shown to increase the Aβ1-42/Aβ1-40 ratio in primary fibroblasts and plasma of affected individuals (15-18).”
BackgroundSubstrate recruitment by γ-secretase
Fukumori, A., Feilen, L. P., & Steiner, H. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.006 · Cited by 22
Choi, D., & Lee, J. (2011) · Brain & Neurorehabilitation · doi:10.12786/bn.2011.4.1.21 · Cited by 19
Velez‐Pardo, C., Jiménez-Del-Río, M., & Lopera, F. J. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00189-x · Cited by 19
Inhibition of β-amyloid formation as a therapeutic strategy
Moore, C. L., & Wolfe, M. S. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.2.135 · Cited by 21
APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease
Wolfe, M. S. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00179-0 · Cited by 24
McMillan, P. J., Leverenz, J. B., & Dorsa, D. M. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00086-3 · Cited by 19
Yliopisto, K., & Helisalmi, S. (1998) · Cited by 33
Recent work on Alzheimer's disease transgenics
Duff, K. (1998) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(98)80132-8 · Cited by 19
Sonar, K., & Mancera, R. L. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c04743 · Cited by 19
Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis
Kamble, S. M., Patil, K. R., & Upaganlawar, A. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00022-4 · Cited by 24
Tian, Y., Shang, Q., Liang, R., & Viles, J. H. (2024) · JACS Au · doi:10.1021/jacsau.3c00687 · Cited by 19
Kaczmarczyk, L., Reichenbach, N., Blank, N., Jonson, M., Dittrich, L., Petzold, G., & Jackson, W. (2021) · Scientific Reports · doi:10.1038/s41598-021-84887-2 · Cited by 16
Bao, Y., Yang, X., Fu, Y., Zhengyan, L., Gong, R., & Lü, W. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00260-3 · Cited by 18
Lazo, N. D., Maji, S. K., Fradinger, E. A., Bitan, G., & Teplow, D. B. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch17 · Cited by 18
FAD Mutations in Amyloid Precursor Protein Do Not Directly Perturb Intracellular Calcium Homeostasis
Stieren, E. S., Werchan, W. P., Ayadi, A. E., Li, F., & Boehning, D. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011992 · Cited by 19
Aβ and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity
Holcomb, L. A., Gordon, M. N., Benkovic, S. A., & Morgan, D. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(99)00086-x · Cited by 20
Differential display analysis of presenilin 1-deficient mouse brains
Liauw, J., Nguyen, V. D., Huang, J., George‐Hyslop, P. S., & Rozmahel, R. F. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00491-6 · Cited by 20
Label-free methods for probing the interaction of clioquinol with amyloid-β
Cheng, X. R., Hung, V. W. S., Scarano, S., Mascini, M., Minunni, M., & Kerman, K. (2012) · Analytical Methods · doi:10.1039/c2ay25123j · Cited by 21
Regional brain evaluation of acetylcholinesterase activity in PS1/A246E transgenic mice
Jazi, R., Lalonde, R., Qian, S., & Strazielle, C. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.11.002 · Cited by 18
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000025 · Cited by 22
Amyloid β Degradation: A Challenging Task for Brain Peptidases
Morelli, L., Bulloj, A., Leal, M. C., & Castaño, E. M. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_6 · Cited by 19
Ren, R. F., Lah, J. J., Diehlmann, A., Kim, E. S., Hawver, D. B., Levey, A. I., Beyreuther, K. T., & Flanders, K. C. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00215-8 · Cited by 19
HouYing, YangQidong, ZhouLin, DuXiaoping, Limin, L., Yuan-mei, ZhouZhiwen, & LiZhenguo (2011) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y11-081 · Cited by 19
“More toxic Ab is generated by g-secretase, possibly in the endoplasmic reticulum (Citron et al. 1997), suggesting further that g-secretase inhibitors can be used as potential targets for treatment of cognitive deficit.”
BackgroundEffects of NK-4 in a Transgenic Mouse Model of Alzheimer's Disease
Ohta, H., Arai, S., Akita, K., Ohta, T., & Fukuda, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030007 · Cited by 17
Unlocking Truths of γ-Secretase In Alzheimer'S Disease: What Is the Translational Potential?
Wolfe, M. S. (2014) · Future Neurology · doi:10.2217/fnl.14.35 · Cited by 18
Gan, K. J., Morihara, T., & Silverman, M. A. (2014) · BioEssays · doi:10.1002/bies.201400131 · Cited by 17
“Although not fully characterized, this shift is driven by familial or sporadic mutations in APP, PS1, or PS2 [14, 15].”
BackgroundProteomic profiling of proteases: tools for granzyme degradomics
van Domselaar, R., de Poot, S. A. H., & Bovenschen, N. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.24 · Cited by 17
He, Q., Huang, G. J., Chen, Y., Wang, X., Huang, Z., & Chen, Z. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2339-0 · Cited by 19
The 5×FAD mouse model of Alzheimer's disease
Ismeurt, C., Giannoni, P., & Claeysen, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00013-6 · Cited by 24
Effect of arctigenin on neurological diseases: A review
Li, M., Jiang, H., Wang, Y., Xu, Z., Xu, H., Chen, Y., Zhu, J., Lin, Z., & Zhang, M. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116642 · Cited by 17
Alleles at the Nicastrin locus modify presenilin 1- deficiency phenotype
Rozmahel, R. F., Mount, H. T. J., Chen, F., Nguyen, V., Huang, J., Erdebil, S., Liauw, J., Yu, G., Hasegawa, H., Gu, Y., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222413999 · Cited by 21
Self-citationBiological Psychiatry and Psychopharmacology
Fountoulakis, K. N., Nimatoudis, I., & Stahl, S. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18323-3_13 · Cited by 17
Cheng, Z., Shang, Y., Xu, X., Dong, Z., Zhang, Y., Du, Z., Lu, X., & Zhang, T. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.12.015 · Cited by 29
Experimental Approaches to Cognitive Disturbance in Alzheimer's Disease
Samuels, S. C., & Davis, K. L. (1998) · Harvard Review of Psychiatry · doi:10.3109/10673229809010950 · Cited by 23
Li, C., Wang, R., Zhang, Y., Hu, C., & Ma, Q. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00410-3 · Cited by 17
Wanngren, J., Lara, P., Öjemalm, K., Maioli, S., Moradi, N., Chen, L., Tjernberg, L. O., Lundkvist, J., Nilsson, I., & Karlström, H. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.04.006 · Cited by 19
“In this report we have studied the impact of several different PS1 FAD mutations on the integration of selected PS1 transmembrane domains and on PS1 active site conformation, and whether any effects translate to a particular amyloid precursor protein (APP) processing phenotype.”
BackgroundLautenschläger, J., & Schierle, G. S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101660 · Cited by 16
Wuli, W., Tsai, S., Chiou, T., & Harn, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041327 · Cited by 16
The Genetics of Alzheimer’s Disease and Parkinson’s Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_21 · Cited by 19
“PSEN1 mutations appear to increase the ratio of Aβ42 to Aβ40, and this appears to result in a change in function that leads to reduced γ-secretase activity (Citron et al., 1997).”
BackgroundModulation of Aβ42 in vivo by γ-secretase modulator in primates and humans
Ling, I., Golde, T. E., Galasko, D. R., & Koo, E. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0137-y · Cited by 16
Thinakaran, G. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:183 · Cited by 16
“…caspase-generated PS1 NTF and CTF were not detected in the brains of transgenic mice expressing a number of FAD-linked mutant PS1 polypeptides (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996; Nakano et al., 1999), arguing against a physiological role for caspase cleavage of PS1.”
BackgroundTransgenic animals as models of neurodegenerative diseases in humans
Theuring, F., Thunecke, M., Kosciessa, U., & Turner, J. D. (1997) · Trends in biotechnology · doi:10.1016/s0167-7799(97)01066-4 · Cited by 16
Raman, A., Lin, X., Suri, M., Hewitt, M., Constantinescu, C. S., & Phillips, M. F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.04.013 · Cited by 16
Younkin, S. G. (1998) · Springer eBooks · doi:10.1007/978-3-642-72103-8_4 · Cited by 17
Molecular biology's impact on our understanding of aging
Mann, D. M. A. (1997) · BMJ · doi:10.1136/bmj.315.7115.1078 · Cited by 20
Recent Advances in the Understanding of the Processing of APP to Beta Amyloid Peptide
SINHA, S., ANDERSON, J., JOHN, V., McCONLOGUE, L., BASI, G., THORSETT, E., & SCHENK, D. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06923.x · Cited by 12
“This evidence includes the observations that multiple missense mutations in the amyloid precursor protein (APP), presenilin-1 (PS-1) or presenilin-2 (PS-2) all result in the overproduction of Aβ42.”
BackgroundSelf-citationAlzheimer's disease, amyotrophic lateral sclerosis, and transgenic mice
Bajaj, N. P. S., Irving, N. G., Leigh, P. N., & MILLER, C. C. J. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.6.711 · Cited by 16
Fernández, S. G., Oria, C. G., Petit, D., Annaert, W. G., Ringman, J. M., Fox, N. C., Ryan, N. S., & Chávez‐Gutiérrez, L. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00832-1 · Cited by 18
Chan, H. H., Koh, R. Y., Lim, C. L., & Leong, C. O. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666191023102422 · Cited by 15
Sun, Y., Yao, Z., & Shi, H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.061 · Cited by 16
Sudo, S., Shiozawa, M., Cairns, N. J., & Wada, Y. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.043 · Cited by 18
Daly, J. J., Lahiri, D. K., Justus, D. E., & Kotwal, G. J. (1998) · Life Sciences · doi:10.1016/s0024-3205(99)80009-5 · Cited by 15
A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment
Kuo, Y., & Rajesh, R. (2017) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2017.05.011 · Cited by 17
Jia, L., Ye, J., Haiyan, L., Wang, W., Zhou, C., Zhang, X., Xu, J., Wang, L., & Jia, J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.01.005 · Cited by 15
Tokuhiro, S., Tomita, T., Iwata, H., Kosaka, T., Saido, T. C., Maruyama, K., & Iwatsubo, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8336 · Cited by 18
Proteolytic processing of Alzheimer’s disease associated proteins
Haass, C., Grünberg, J., Capell, A., Wild‐Bode, C., Leimer, U., Walter, J., Yamazaki, T., Ihara, I., Zweckbronner, I., Jakubek, C., et al. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_14 · Cited by 18
Genetic testing for Alzheimerʼs disease: how close is reality?
Blennow, K., & Skoog, I. (1999) · Current Opinion in Psychiatry · doi:10.1097/00001504-199907000-00019 · Cited by 15
Sinnige, T., Stroobants, K., Dobson, C. M., & Vendruscolo, M. (2020) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583520000104 · Cited by 17
Mohan, G. S., & Kumar, R. (2025) · Aging and Disease · doi:10.14336/ad.2025.0472 · Cited by 29
Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology
Zhu, Y., Obregon, D. F., Hou, H., Giunta, B. N., Ehrhart, J. C., Fernandez, F., Mori, T., Nikolic, W. V., Zhao, Y., Morgan, D., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00962.x · Cited by 16
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.